全文获取类型
收费全文 | 5448篇 |
免费 | 371篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 91篇 |
儿科学 | 195篇 |
妇产科学 | 131篇 |
基础医学 | 815篇 |
口腔科学 | 94篇 |
临床医学 | 506篇 |
内科学 | 1160篇 |
皮肤病学 | 144篇 |
神经病学 | 436篇 |
特种医学 | 375篇 |
外科学 | 651篇 |
综合类 | 51篇 |
预防医学 | 443篇 |
眼科学 | 123篇 |
药学 | 324篇 |
中国医学 | 6篇 |
肿瘤学 | 284篇 |
出版年
2021年 | 50篇 |
2020年 | 46篇 |
2019年 | 57篇 |
2018年 | 90篇 |
2017年 | 50篇 |
2016年 | 83篇 |
2015年 | 103篇 |
2014年 | 128篇 |
2013年 | 187篇 |
2012年 | 228篇 |
2011年 | 226篇 |
2010年 | 153篇 |
2009年 | 159篇 |
2008年 | 229篇 |
2007年 | 236篇 |
2006年 | 233篇 |
2005年 | 219篇 |
2004年 | 196篇 |
2003年 | 215篇 |
2002年 | 209篇 |
2001年 | 185篇 |
2000年 | 206篇 |
1999年 | 175篇 |
1998年 | 98篇 |
1997年 | 78篇 |
1996年 | 60篇 |
1995年 | 65篇 |
1994年 | 55篇 |
1993年 | 61篇 |
1992年 | 99篇 |
1991年 | 94篇 |
1990年 | 105篇 |
1989年 | 109篇 |
1988年 | 101篇 |
1987年 | 80篇 |
1986年 | 86篇 |
1985年 | 81篇 |
1984年 | 50篇 |
1983年 | 57篇 |
1981年 | 41篇 |
1980年 | 37篇 |
1979年 | 65篇 |
1978年 | 48篇 |
1977年 | 43篇 |
1975年 | 41篇 |
1974年 | 40篇 |
1973年 | 59篇 |
1972年 | 51篇 |
1970年 | 38篇 |
1969年 | 37篇 |
排序方式: 共有5829条查询结果,搜索用时 15 毫秒
91.
C. Chabannon K. Cornetta J. P. Lotz C. Rosenfeld M. Shlomchik S. Yanovitch J. P. Marolleau G. Sledge G. Novakovitch E. F. Srour B. Burtness J. Camerlo G. Gravis J. Lee-Fischer C. Faucher I. Chabbert D. Krause D. Maraninchi B. Mills L. Kunkel F. Oldham D. Blaise P. Viens 《British journal of cancer》1998,78(7):913-921
Seventy-one patients with poor-prognosis breast cancer were enrolled after informed consent in a multicentre randomized study to evaluate the use of selected peripheral blood CD34+ cells to support haematopoietic recovery following high-dose chemotherapy. Patients who responded to conventional chemotherapy were mobilized with chemotherapy (mainly high-dose cyclophosphamide) and/or recombinant human granulocyte colony-stimulating factor (rhG-CSF). Patients who reached the threshold of 20 CD34+ cells per microl of peripheral blood underwent apheresis and were randomized at that time to receive either unmanipulated mobilized blood cells or selected CD34+ cells. For patients in the study arm, CD34+ cells were selected from aphereses using the Isolex300 device. Fifteen patients failed to mobilize peripheral blood progenitors and nine other patients were excluded for various reasons. Forty-seven eligible patients were randomized into two comparable groups. CD34+ cells were selected from aphereses in the study group. Haematopoietic recovery occurred at similar times in both groups. No side-effect related to the infusion of selected cells was observed. The frequency of epithelial tumour cells in aphereses was low (8 out of 42 evaluated patients), as determined by immunocytochemistry. We conclude that selected CD34+ cells safely support haematopoietic recovery following high-dose chemotherapy in patients with poor-prognosis breast cancer. 相似文献
92.
Attention deficit hyperactivity disorder: binding of [99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment 总被引:11,自引:0,他引:11
Dresel S Krause J Krause KH LaFougere C Brinkbäumer K Kung HF Hahn K Tatsch K 《European journal of nuclear medicine》2000,27(10):1518-1524
Involvement of the dopaminergic system has been suggested in patients suffering from attention deficit hyperactivity disorder (ADHD) since the symptoms can be successfully treated with methylphenidate, a potent blocker of the dopamine transporter (DAT). This study reports the findings on the status of the DAT in adults with ADHD before and after commencement of treatment with methylphenidate, as measured using [99mTc]TRODAT-1. Seventeen patients (seven males, ten females, aged 21-64 years, mean 38 years) were examined before and after the initiation of methylphenidate treatment (3x5 mg/day). All subjects were injected with 800 MBq [99mTc]TRODAT-1 and imaged 3 h p.i. Single-photon emission tomography (SPET) scans were acquired using a triple-headed gamma camera. For semiquantitative evaluation of the DAT, transverse slices corrected for attenuation were used to calculate specific binding in the striatum, with the cerebellum used as background [(STR-BKG)/BKG]. Data were compared with an age-matched control group. It was found that untreated patients presented with a significantly increased specific binding of [99mTc]TRODAT-1 to the DAT as compared with normal controls [(STR-BKG)/BKG: 1.43+/-0.18 vs 1.22+/-0.06, P<0.001]. Under treatment with methylphenidate, specific binding decreased significantly in all patients [(STR-BKG)/BKG: 1.00+/-0.14, P<0.001]. Our findings suggest that the number of DAT binding sites is higher in drug-naive patients suffering from ADHD than in normal controls. The decrease in available DAT binding sites under treatment with methylphenidate correlates well with the improvement in clinical symptoms. The data of this study help to elucidate the complex dysregulation of the dopaminergic neurotransmitter system in patients suffering from ADHD and the effect of treatment with psychoactive drugs. 相似文献
93.
Janet Li Paul Roche Jenean Spencer Ivan Bastian Amanda Christensen Mark Hurwitz Anastasios Konstantinos Vicki Krause Moira McKinnon Avner Misrachi Graham Tallis Justin Waring 《Communicable diseases intelligence》2004,28(4):464-473
The National Notifiable Disease Surveillance System (NNDSS) received 982 tuberculosis (TB) notifications in 2003, of which 947 were new cases, 33 were relapses and two were cases with unknown history. The incidence of TB in Australia has remained at a stable rate since 1985 and was 4.9 cases per 100,000 population in 2003. The high-incidence groups remain people born overseas and Indigenous Australians at 19.9 and 8.7 cases per 100,000 population, respectively. By contrast the incidence in non-Indigenous Australians was 0.9 per 100,000. Comparison of the 2003 TB notification data against the performance indicators set by National Tuberculosis Advisory Committee highlights that enhanced TB control measures should be considered among these high-risk groups. 相似文献
94.
95.
Analysis of the S810L point mutation of the mineralocorticoid receptor in patients with pregnancy-induced hypertension. 总被引:1,自引:0,他引:1
Annette Schmider-Ross M Wirsing U Büscher H Neitzel M Krause W Henrich A Reles J W Dudenhausen 《Hypertension in pregnancy》2004,23(1):113-119
OBJECTIVE: A missense mutation at codon 810 (Ser --> Leu) of the mineralocorticoid receptor was recently observed in a family with early manifestation of hypertension. Our objective was to determine if this mineralocorticoid receptor alterations is prevalent in patients with pregnancy-induced hypertension. METHODS: Thirty-eight women with hypertension during pregnancy were tested for the mineralocorticoid receptor gene mutation. DNA was extracted out of blood leucocytes. PCR and automated DNA sequencing were used to analyze exon 6 for the S810L missense mutation. Anamnestical data concerning cardiovascular risk factors and family history were evaluated with a questionnaire. Pregnancy course and outcome were documented in all cases. RESULTS: In 33 patients with pregnancy-induced hypertension and in five patients with exacerbation of preexisting hypertension in pregnancy no point mutations were found at codon 810 in exon 6. CONCLUSIONS: Our data suggest that the S810L missense mutation of the mineralocorticoid receptor does not play a major role in the etiology of pregnancy-induced hypertension in a German /Turkish population. 相似文献
96.
97.
Lemmer JH Metzdorff MT Krause AH Martin MA Okies JE Hill JG 《The Annals of thoracic surgery》2000,69(1):90-95
BACKGROUND: Although the platelet antiaggregant abciximab is frequently used with percutaneous coronary interventions, results of emergency coronary artery bypass graft operations in patients recently treated with abciximab are poorly characterized. METHODS: During a 29-month period, 12 patients required emergency coronary artery bypass grafting within 12 hours (mean, 1.9 hours) of abciximab therapy. Our full standard heparin dose regimen was used (mean heparin dose, 53,000 U per patient). Each patient received a single platelet transfusion dose after protamine administration, and further blood products were transfused as necessary. Clinical outcome and transfusion requirements were compared with predicted results based on risk-adjusted historical patients. RESULTS: No patients died and none were returned to the operating room for coagulopathy-related bleeding. Per patient transfusion requirements were as follows: red blood cells, 3.6 units; apheresis platelets, 1.4 units; and fresh frozen plasma, 1.5 units. As compared with predicted values, there was no excessive incidence of mortality, stroke, or red blood cell transfusion requirements. CONCLUSIONS: Emergency coronary artery bypass graft operations using full-dose heparin can be performed successfully in acutely ischemic abciximab-treated patients. Prophylactic transfusion of platelets after protamine administration appears to be useful. 相似文献
98.
L. Kurch D. Hasenclever R. Kluge T. Georgi L. Tchavdarova M. Golombeck O. Sabri A. Eggert W. Brenner K.W. Sykora F.M. Bengel C. Rossig D. Krholz M. Schfers T. Feuchtinger P. Bartenstein R.A. Ammann T. Krause C. Urban R. Aigner S. Gattenlhner W. Klapper C. Mauz‐Krholz 《Pediatric blood & cancer》2019,66(3)
99.
U Ulrich M Nehmzow B Krause G G?retzlehner F D?cke 《Zentralblatt für Gyn?kologie》1990,112(20):1295-1298
Increased hypothalamic dopamine turnover may prevent the ovulatory LH peak by different mechanisms and may in this way result in anovulation. Ten patients with anovulatory menstrual cycles who had been treated with clomiphene citrate without success were given the dopaminolytic drug pimozide (Antalon) at a dose of 5 mg/day orally either from day 7 to day 11 (7 women; group 1) or from day 11 to day 15 of the menstrual cycle (4 women; group 2). One patient from group 2 ovulated during the treatment cycle. A further woman from this group exhibited an LH peak, but did not ovulate, whereas a slow increase of the circulating LH level was recorded in the remaining two patients. Systematic investigations should clarify whether introduction of dopaminolytic therapy in the treatment of hypothalamic anovulation may be justified. 相似文献
100.
Sarah E. Coupland Sonja Klebe Anne-Christine Karow Lothar Krause Heinrich Kruse Robert R. Bartlett Friedrich Hoffmann 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》1994,232(10):622-627
Background: The isoxal derivative, leflunomide (LF), is a new potent immunosuppressive which has been shown to be effective in preventing autoimmune disorders and reactions leading to organ transplantation rejection. LF is thought to antagonise cytokine activity and thereby to interfere with T-helper-cell-dependent B- and T-lymphocyte proliferation. Methods: We used LF to treat corneal allograft rejection in the rat, comparing its effect with that of cyclosporin A (CSA). Corneal buttons were grafted from Lewis/Brown Norway rats to Lewis recipients. Animals were randomly assigned to the following treatment groups: I, untreated; II, CSA (10 mg/kg i.m.); III, LF (2.5 mg/kg p.o.); IV, LF (5 mg/kg p.o.); V, LF (10 mg/kg p.o.); VI, combined therapy (LF 10 mg/kg p.o. and CSA 10 mg/kg i.m). Treatment began on the first postoperative day and was continued until rejection occurred. Results: The mean graft rejection time in the untreated allogeneic group was 12 days. A significant delay in graft rejection was observed in all treatment groups compared with group I (P<0.001). Further, the delay in graft rejection resulting from combined therapy (group VI) was statistically significant compared with all other groups (P<0.001). Conclusion: These results suggest that (a) LF when used alone is as effective as CSA in treating corneal allograft rejection in the rat, and (b) when LF and CSA are combined they are more effective than either drug alone in the prolongation of allograft survival.Presented in abstract form at the Berlin-Brandenburg Eye Congress, 4–5 December 1993. None of the authors has any proprietary or financial interests in the compound leflunomide 相似文献